The emerging role of regulatory T cells following lung transplantation

Gauthier, Jason M.; Harrison, M. Shea; Krupnick, Alexander S.; Gelman, Andrew E.; Kreisel, Daniel

doi:10.1111/imr.12801

Cited by 11 publications

(4 citation statements)

References 179 publications

(311 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regulatory T cell therapies are remarkably promising in transplantation and have been reviewed recently (11,12,(72)(73)(74)(75)(76)(77)(78). To avoid broad immunosuppression and the risk of infection with polyclonal Tregs, one strategy is to focus on antigen-specific Treg cells, which induced tolerance in animal models and can also be expanded from patients (64).…”

Section: Targeting Enclysis In Transplantationmentioning

confidence: 99%

Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer

et al. 2021

View full text Add to dashboard Cite

Persistent liver inflammation can lead to cirrhosis, which associates with significant morbidity and mortality worldwide. There are no curative treatments beyond transplantation, followed by long-term immunosuppression. The global burden of end stage liver disease has been increasing and there is a shortage of donor organs, therefore new therapies are desperately needed. Harnessing the power of the immune system has shown promise in certain autoimmunity and cancer settings. In the context of the liver, regulatory T cell (Treg) therapies are in development. The hypothesis is that these specialized lymphocytes that dampen inflammation may reduce liver injury in patients with chronic, progressive diseases, and promote transplant tolerance. Various strategies including intrinsic and extracorporeal expansion of Treg cells, aim to increase their abundance to suppress immune responses. We recently discovered that hepatocytes engulf and delete Treg cells by enclysis. Herein, we propose that inhibition of enclysis may potentiate existing regulatory T cell therapeutic approaches in patients with autoimmune liver diseases and in patients receiving a transplant. Moreover, in settings where the abundance of Treg cells could hinder beneficial immunity, such us in chronic viral infection or liver cancer, enhancement of enclysis could result in transient, localized reduction of Treg cell numbers and tip the balance towards antiviral and anti-tumor immunity. We describe enclysis as is a natural process of liver immune regulation that lends itself to therapeutic targeting, particularly in combination with current Treg cell approaches.

show abstract

Section: Targeting Enclysis In Transplantationmentioning

confidence: 99%

Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Although lung transplantation is currently the only treatment for end-stage lung disease [ 270 ], the survival rate after lung transplantation is significantly lower compared with that of other organs. This is due to the high immunogenicity of the lung and continuous exposure to the external environment [ 271 ]. In the early 1980s, the technical obstacles of lung transplantation were overcome.…”

Section: The Role Of Treg Cells In Human Lung Diseasesmentioning

confidence: 99%

Regulatory T cells in lung disease and transplantation

Lao,

Chen,

Tang

et al. 2023

Bioscience Reports

View full text Add to dashboard Cite

Pulmonary disease can refer to the disease of the lung itself or the pulmonary manifestations of systemic diseases, which are often connected to the malfunction of the immune system. Regulatory T (Treg) cells have been shown to be important in maintaining immune homeostasis and preventing inflammatory damage, including lung diseases. Given the increasing amount of evidence linking Treg cells to various pulmonary conditions, Treg cells might serve as a therapeutic strategy for the treatment of lung diseases and potentially promote lung transplant tolerance. The most potent and well-defined Treg cells are Foxp3-expressing CD4+ Treg cells, which contribute to the prevention of autoimmune lung diseases and the promotion of lung transplant rejection. The protective mechanisms of Treg cells in lung disease and transplantation involve multiple immune suppression mechanisms. This review summarises the development, phenotype and function of CD4+Foxp3+ Treg cells. Then we focus on the therapeutic potential of Treg cells in preventing lung disease and limiting lung transplant rejection. Furthermore, we discussed the possibility of Treg cell utilization in clinical applications. This will provide an overview of current research advances in Treg cells and their relevant application in clinics.

show abstract

“…In the case of patients who underwent lung transplants, the presence of iBALT with active GCs can lead to graft rejection [ 30 ] due to the development of antibody-mediated rejection [ 31 ].…”

Section: Bronchus-associated Lymphoid Tissue (Balt)mentioning

confidence: 99%

Short histological kaleidoscope – recent findings in histology. Part II

Constantin

Boșca²,

Melincovici³

et al. 2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

This article focuses on the latest histological knowledge in the field regarding the peripheral lymphoid system [mucosa-associated lymphoid tissue (MALT), bronchus-associated lymphoid tissue (BALT), gut-associated lymphoid tissue (GALT)], the thymus stroma, some of the various corpuscles of the human body (Hassall's corpuscles in thymus, arenaceous corpuscles in pineal gland, corpora amylacea in prostate and other locations) and Fañanas glial cells in the cerebellum.

show abstract

The emerging role of regulatory T cells following lung transplantation

Cited by 11 publications

References 179 publications

Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer

Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer

Regulatory T cells in lung disease and transplantation

Short histological kaleidoscope – recent findings in histology. Part II

Contact Info

Product

Resources

About